AbbVie Inc (ABBV)vsNovavax Inc (NVAX)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
NVAX
Novavax Inc
$7.93
-0.56%
HEALTHCARE · Cap: $1.31B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5344% more annual revenue ($61.16B vs $1.12B). NVAX leads profitability with a 39.2% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
NVAX
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Intrinsic value data unavailable for NVAX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Revenue surging 66.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -898.0% — below average capital efficiency
Earnings declined 38.1%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : NVAX
The strongest argument for NVAX centers on P/E Ratio, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.2% and operating margin at 14.2%. Revenue growth of 66.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : NVAX
The primary concerns for NVAX are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while NVAX is a growth play — different risk/reward profiles.
NVAX carries more volatility with a beta of 2.65 — expect wider price swings.
NVAX is growing revenue faster at 66.6% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Novavax Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?